Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Celldex Therapeutics (CLDX) Invested Capital (2016 - 2025)

Celldex Therapeutics has reported Invested Capital over the past 16 years, most recently at $527.2 million for Q4 2025.

  • Quarterly results put Invested Capital at $527.2 million for Q4 2025, down 29.43% from a year ago — trailing twelve months through Dec 2025 was $527.2 million (down 29.43% YoY), and the annual figure for FY2025 was $527.2 million, down 29.43%.
  • Invested Capital for Q4 2025 was $527.2 million at Celldex Therapeutics, down from $598.4 million in the prior quarter.
  • Over the last five years, Invested Capital for CLDX hit a ceiling of $838.6 million in Q1 2024 and a floor of $182.3 million in Q2 2021.
  • Median Invested Capital over the past 5 years was $424.3 million (2021), compared with a mean of $479.6 million.
  • Biggest five-year swings in Invested Capital: skyrocketed 218.54% in 2024 and later fell 29.43% in 2025.
  • Celldex Therapeutics' Invested Capital stood at $419.5 million in 2021, then decreased by 22.24% to $326.2 million in 2022, then soared by 31.57% to $429.2 million in 2023, then surged by 74.06% to $747.0 million in 2024, then fell by 29.43% to $527.2 million in 2025.
  • The last three reported values for Invested Capital were $527.2 million (Q4 2025), $598.4 million (Q3 2025), and $655.4 million (Q2 2025) per Business Quant data.